Lastly, the absence of clinical validation means the relevance of MALAT1 as a therapeutic target remains uncertain
Joining Risinger in lowering price targets on Lilly stock: B of A Securities (Geoff Meacham) Down 4% from $1,150 to $1,100) but maintaining Buy rating
Under oxidative stress these three systems work in concert to detoxify ROS and lipid peroxides, maintain protein structure and function via thiol repair, prevent activation of redox-sensitive inflammatory pathways, and preserve mitochondrial membrane integrity and prevent apoptosis
further notes that a restricted maintenance dose of just four injections per year is what is normally allowed, which can leave people physically and mentally unable to contribute to either family or society, and lead to permanent neurological damage
The choice between them isn't about which one is "stronger." It's about which one is the right tool for a specific research question